Following long-time chief José Almeida’s retirement earlier this year, Baxter announced it has officially named a new CEO. | ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Chugai, a Japanese company majority owned by Roche, has identified Gero’s platform as complementary to its own capabilities.

University of Minnesota spinout Fasikl has obtained an FDA clearance for its artificial-intelligence-powered wearable for ...

In the July 2 release, 4DMT explained that the 25% layoffs are part of a move to “streamline operations to offset additional ...

Field Medical has generated another $35 million in venture capital funding for its cardiac pulsed field ablation system to support the launch of a pivotal trial. | The series B financing comes quickly ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

AbbVie is on board with the idea. The Big Pharma will pay up to $2.1 billion in cash at closing to acquire Capstan. In return ...

Catalio Capital Management has closed its fourth venture fund with more than $400 million that will be used in part to launch ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...